Suppr超能文献

益生菌、益生元及合生元补充剂对贫血个体的疗效:一项随机对照试验的系统评价和荟萃分析

Efficacy of probiotic, prebiotic, and synbiotics supplements in individuals with anemia: a systematic review and meta-analysis of randomized controlled trials.

作者信息

Hu Qian, Liu Ying, Fei Youmei, Zhang Jingping, Yin Shao, Zou Hui, Zhu Fengya

机构信息

Department of Hematology, Meishan City People's Hospital, Meishan, China.

Chengdu University of Traditional Chinese Medicine, Chengdu, China.

出版信息

BMC Gastroenterol. 2024 Dec 23;24(1):472. doi: 10.1186/s12876-024-03562-8.

Abstract

INTRODUCTION

Anemia is a common global health problem, particularly in impoverished regions, with a high incidence rate. The condition is multifactorial, with iron deficiency being one of the most prevalent causes. Current treatment for anemia often relies on iron supplements or erythropoiesis-stimulating agents, although these therapies may show limited efficacy for some patients. Recent evidence suggests that probiotics, prebiotics, and synbiotics, as microbiome modulators, hold significant potential in the treatment of anemia. These interventions may enhance iron absorption and improve overall blood health through their impact on gut microbiota, thus providing an alternative or complementary approach to conventional treatments.

METHODS

Six databases, including the Cochrane Central Register of Controlled Trials, Embase, PubMed, Web of Science (WOS), China National Knowledge Infrastructure (CNKI), and WangFang data library, were searched up to November 20, 2024. Studies published in English and Chinese were included. We included randomized controlled trials (RCTs) evaluating the effects of probiotics, prebiotics, or synbiotics in treating anemia. The experimental groups received probiotics, prebiotics, or synbiotics, while the control groups received placebo, alternative treatments, or no treatment. The primary outcome was hemoglobin (Hb) levels. Secondary outcomes included serum iron (SI) and serum ferritin (SF). A descriptive analysis was conducted for studies where meta-analysis was not feasible. The GRADE tool was used to assess the quality of evidence, and the Cochrane guidelines were employed to evaluate the risk of bias in each study.

RESULTS

Seven studies were included comprising a total of eight RCTs, with the main types of anemia being iron deficiency anemia (IDA) and anemia of chronic kidney disease (CKD), involving 632 patients. The analysis revealed that probiotics, prebiotics, or synbiotics significantly improved Hb levels in patients with anemia (WMD = 10.760, 95% CI: 4.593 to 16.747, p = 0.001), though heterogeneity was high (I² = 96.5%). Two RCTs (n = 120 participants) reported significant increases in serum iron levels in the probiotic group (WMD = 3.835, 95% CI: 3.271 to 4.400), with moderate heterogeneity (I² = 38.7%). Two RCTs (n = 192 participants) reported no significant differences were observed between the groups in serum ferritin levels (WMD = 8.048, p = 0.115), and heterogeneity remained high (I² = 62.6%). Subgroup analyses revealed that probiotics improved Hb levels in renal and iron-deficiency anemia, as well as across different doses. The synbiotic group showed consistent efficacy (I² = 0%), while the prebiotic group did not exhibit significant effects, with extremely high heterogeneity (I² = 99.3%). This indicates that heterogeneity may stem from variations in intervention types, and the results should be interpreted with caution.

CONCLUSION

There is moderate-quality evidence suggesting that probiotics, prebiotics, and synbiotics may improve anemia management, particularly by enhancing Hb levels. Further high-quality RCTs are required to explore the specific role of synbiotics in anemia management, including their comparative efficacy against probiotics and prebiotics alone, and their impact on gastrointestinal factors such as gut microbiota modulation and inflammation reduction.

SYSTEMATIC REVIEW REGISTRATION

PROSPERO CRD42024590073.

摘要

引言

贫血是一个常见的全球健康问题,在贫困地区尤为高发。贫血是多因素导致的,缺铁是最常见的原因之一。目前贫血的治疗通常依赖铁补充剂或促红细胞生成素,尽管这些疗法对某些患者可能疗效有限。最近的证据表明,作为微生物群调节剂的益生菌、益生元及合生元在贫血治疗中具有巨大潜力。这些干预措施可能通过影响肠道微生物群来增强铁吸收并改善整体血液健康,从而为传统治疗提供替代或补充方法。

方法

检索了六个数据库,包括Cochrane对照试验中心注册库、Embase、PubMed、科学网(WOS)、中国知网(CNKI)和万方数据库,检索截至2024年11月20日发表的研究。纳入英文和中文发表的研究。我们纳入了评估益生菌、益生元或合生元治疗贫血效果的随机对照试验(RCT)。试验组接受益生菌、益生元或合生元,而对照组接受安慰剂、替代治疗或不治疗。主要结局是血红蛋白(Hb)水平。次要结局包括血清铁(SI)和血清铁蛋白(SF)。对于无法进行荟萃分析的研究进行描述性分析。使用GRADE工具评估证据质量,并采用Cochrane指南评估每项研究的偏倚风险。

结果

共纳入7项研究,包括8项随机对照试验,主要贫血类型为缺铁性贫血(IDA)和慢性肾脏病(CKD)贫血,涉及632例患者。分析显示,益生菌、益生元或合生元显著提高了贫血患者血红蛋白水平(加权均数差[WMD]=10.760,95%置信区间:4.593至16.747,p=0.001),尽管异质性较高(I²=96.5%)。两项随机对照试验(n=120名参与者)报告益生菌组血清铁水平显著升高(WMD=3.835,95%置信区间:3.271至4.400),异质性中等(I²=38.7%)。两项随机对照试验(n=192名参与者)报告两组血清铁蛋白水平无显著差异(WMD=8.048,p=0.115),异质性仍然较高(I²=62.6%)。亚组分析显示,益生菌可提高肾性贫血和缺铁性贫血患者的血红蛋白水平,且不同剂量均有此效果。合生元组显示出一致的疗效(I²=0%),而益生元组未显示出显著效果,异质性极高(I²=99.3%)。这表明异质性可能源于干预类型的差异,结果应谨慎解读。

结论

有中等质量的证据表明,益生菌、益生元及合生元可能改善贫血治疗,特别是通过提高血红蛋白水平。需要进一步开展高质量的随机对照试验,以探索合生元在贫血治疗中的具体作用,包括其与单独使用益生菌和益生元相比的疗效,以及对胃肠道因素如肠道微生物群调节和炎症减轻的影响。

系统评价注册

PROSPERO CRD42024590073

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3aff/11668107/8a6076e6ff03/12876_2024_3562_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验